Key terms
About EVAX
Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest EVAX news
Yesterday
10:27am ET
Evaxion Biotech Advances Personalized Cancer Vaccine
Yesterday
8:03am ET
Evaxion Biotech says first patient completed dosing with personalized EVX-01
Apr 03
6:40am ET
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Genprex (GNPX) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
Apr 03
6:31am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evaxion Biotech (EVAX), 60 Degrees Pharmaceuticals, Inc. (SXTP) and Genprex (GNPX)
Apr 02
11:34am ET
Ladenburg upgrades Evaxion Biotech to Buy into 2024 readouts
Apr 02
11:28am ET
Evaxion Biotech upgraded to Buy from Neutral at Ladenburg
Apr 02
8:27am ET
Evaxion’s Promising Vaccine Candidate Battles Superbug
Apr 02
7:09am ET
Evaxion Biotech announces conclusion of studies on EVX-B1 vaccine candidate
Mar 29
9:57am ET
Evaxion Biotech Announces Upcoming Annual Meeting
Mar 27
7:34am ET
Evaxion Biotech reports Q4 EPS (16c) vs (29c) last year
Mar 20
6:26am ET
Buy Rating Affirmed for Evaxion Biotech Amid AI-Driven Vaccine Development Milestones
Mar 19
9:27am ET
Evaxion Biotech Reveals AI-Driven Vaccine Innovations
Mar 19
7:36am ET
Evaxion Biotech hosts R&D day, unveils potential of AI-Immunology platform
Feb 20
7:37am ET
Evaxion announces completion of initial phases of collaboration with MSD
Feb 12
6:25am ET
Buy Rating for Evaxion Biotech: AI Revolutionizing Immunotherapy and Vaccine Development
Feb 12
6:13am ET
Evaxion Biotech initiated with a Buy at H.C. Wainwright
Feb 07
8:38am ET
Evaxion Biotech regains compliance with Nasdaq minimum bid price rule
Feb 01
9:21am ET
Evaxion Biotech prices 3.75M ADSs at $4.00 in public offering
Jan 24
8:37am ET
Evaxion to develop tailored cancer vaccines based on AI-discovered targets
Jan 22
11:56am ET
Evaxion Biotech trading resumes
Jan 22
11:51am ET
Evaxion Biotech trading halted, volatility trading pause
Jan 19
7:50pm ET
Evaxion Biotech trading halted, news pending
No recent press releases are available for EVAX
EVAX Financials
Key terms
Ad Feedback
EVAX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
EVAX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
